Emera Incorporated (TSE:EMA) Ratings Coverage
Total analysts of 2 have positions in Emera Incorporated (TSE:EMA) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since February 20, 2019 according to StockzIntelligence Inc Emera Incorporated has 2 analyst reports. On Tuesday, February 19 the firm earned “Buy” rating by BMO Capital Markets. On Wednesday, February 20 the rating was maintained by RBC Capital Markets with “Buy”. Listed here are Emera Incorporated (TSE:EMA) PTs and latest ratings.
19/02/2019 Broker: BMO Capital Markets Rating: Buy New Target: $48 Maintain
20/02/2019 Broker: RBC Capital Markets Rating: Buy New Target: $53 Maintain
Ticker’s shares touched $46.99 during the last trading session after 0.36% change.Emera Incorporated has volume of 184,747 shares. Since March 1, 2018 EMA has 0.00% and is . The stock the S&P 500 by 0.00%.
Emera Incorporated, an energy and services company, through its subsidiaries, engages in the generation, transmission, and distribution of electricity to various customers.The firm is valued at $10.95 billion. The firm is also involved in gas transmission and utility energy services businesses; and the provision of energy marketing, trading, and other energy asset management services.The P/E ratio is 15.45. In addition, it transports re-gasified liquefied natural gas to clients in the northeastern United States through its 145-kilometre pipeline in New Brunswick.
For more Emera Incorporated (TSE:EMA) news brought out briefly go to: Midasletter.com, Warriortradingnews.com, , Nasdaq.com or Business.Financialpost.com. The titles are as follows: “Canopy Growth Corp (TSE:WEED) Straddling 200-Day MA As Sector Weakness Abounds – Midas Letter” brought out on November 20, 2018, “Tilray Finalizes $35 Million Greenhouse Grower Purchase – Warrior Trading News” on February 20, 2019, “What Makes Manappuram Finance Limited (NSE:MANAPPURAM) A Great Dividend Stock? – Yahoo Finance” with a publish date: June 20, 2018, “7 Canadian Utility Stocks That Are Perfect For Retirees – Nasdaq” and the last “Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD – Financial Post” with publication date: December 14, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.